Business
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
REDWOOD CITY, Calif., April 11, 2025--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
About this update from Exicure, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2431,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/2fc10e4e872671809235282b86079137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HOvPT45UlbPIA7KGQIQEAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2fc10e4e872671809235282b86079137","width":960,"height":237},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TQsmm4bt_Kly_XGhOEDtrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2fc10e4e872671809235282b86079137","width":1200,"height":296}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., April 11, 2025--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor.","length":178,"tagName":"p"},{"type":"text","content":"Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that GPC-100, when paired with modern AML treatment regimens, can further improve outcomes in this high unmet need clinical indication. A Phase 1 chemosensitization study involving 15 patients with relapsed or refractory AML was previously conducted by Taigen, the original developer of GPC-100. In that study, GPC-100 was combined with fludarabine and cytarabine to evaluate safety and preliminary efficacy. Preclinical data published by Dr. Pam Becker at City of Hope in collaboration with GPCR Therapeutics USA, a subsidiary of Exicure, demonstrated that dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade led to improved chemotherapy response (2024 American Society of Hematology Annual meeting : Poster #2758). This therapeutic approach is protected by an expanded patent portfolio granted in the United States, Japan, Australia, and Taiwan.","length":1009,"tagName":"p"},{"type":"text","content":"In addition to AML, GPC-100 is currently being evaluated in an ongoing Phase 2 trial in patients with multiple myeloma (MM) undergoing autologous stem cell transplant (ASCT; NCT05561751). Clinical trial results for this study are expected in Q4 2025.","length":250,"tagName":"p"},{"type":"text","content":"Current Evaluating P...